Biomarker Bulletin: July 5, 2011

July 5, 2011 | by

Biomarker Bulletin is an occasionally recurring update of news focused on biomarkers aggregated at BiomarkerCommons.org. Biomarkers are physical, functional or biochemical indicators of normal physiological or disease processes. The individualization of disease management — personalized medicine — is dependent on developing biomarkers that promote specific clinical domains, including early detection, risk, diagnosis, prognosis and predicted response to therapy.

Biomarker Commons

  • TCGA Study Brings Ovarian Cancer Patients Closer to Personalized Medicine

    In the June 30 issue of Nature, researchers from The Cancer Genome Atlas (TCGA) Research Network provide a large-scale integrative report on genetic mutations and pathways that distinguish the most common and aggressive type of ovarian cancer from other types of ovarian cancer as well as from other solid tumors. The disease is not defined by one or few cancer-driving genes but rather numerous mutations that individually occur in only a small number of cases. Given the degree of genomic disarray, the study results suggest that genomic structural variation is the driver of ovarian cancer. The findings may be helpful in guiding physicians to choose experimental treatments that are most likely to target molecular alterations effectively in patients with high-grade serous ovarian adenocarcinoma.

  • BGI Expanding Proteomics Services to Include Mass Spectrometry

    Earlier this month, Adam Bonislawski at GenomeWeb’s Proteomonitor reported that China-based BGI intends to expand its proteomics offerings and buy ~50 new mass spectrometers over the next two years. This diversification into clinical and drug-development services is a forward-thinking move for the genomics/bioinformatics giant and one that should be taken seriously by current proteomics service providers.

  • DHMRI Establishes Immune Monitoring Laboratory for Biomarker Discovery and Development

    Last week, the David H. Murdock Research Institute (DHMRI) announced that it acquired the Immune Tolerance Institute, Inc. (ITI) as a next step in its continued growth. The DHMRI provides integrated, state-of-the-art genomic, cellular, proteomic and bioinformatics technology platforms as a major resource for a range of academic and industry partners undertaking both preclinical and clinical research.

  • NINDS to Fund Biomarker Clinical Study for Spinal Muscular Atrophy

    Earlier this month, the National Institute of Neurological Disorders and Stroke (NINDS) announced a funding opportunity and invited applications for a study of candidate biomarkers in Spinal Muscular Atrophy (SMA). The goals of the SMA biomarker validation study are to: (1) evaluate biomarkers and clinical outcomes longitudinally across a spectrum of SMA cases; (2) establish a clinical outcomes and biomarker database; and (3) contribute samples to the NINDS biorepository at the Coriell Institute for Medical Research to capture and share methods and pre-competitive data.

  • SciClips Launches Biomarker and Drug Discovery Protocols Database

    SciClips is an open innovation platform that enables scientists and researchers to collaborate and share research and ideas. Following up on a diagnostic and prognostic biomarker database released earlier this year, SciClips has launched a second database constisting of biomarker and drug discovery research protocols.

Cancer Research Blog Carnival #13 – Stand Up To Cancer

September 5, 2008 | by

Welcome to the 13th edition of the Cancer Research Blog Carnival, the blog carnival devoted to cancer research.

There’s a revolution occurring on the Web: those “authoritative” articles written on traditional, static websites are being replaced with blogs, wikis and online social networks. In the sphere of health, medicine and information technology, this “real-time Web” consists of many who are professionals in the field; their posts are listed below.
In the digital age, these are the characteristics of new media: recent, relevant, reachable and reliable.

Everyone knows that cancer is a devastating disease. What many people don’t know is that cancer kills more than 1,500 people a day; that’s one person every minute. Tonight, Stand Up To Cancer, a one-hour fundraising event, will be simulcast on all three major U.S. networks. The goal of Stand Up To Cancer (SU2C) is to enable cutting-edge research aimed at finding a cure to all types of cancer and making cancer part of the national debate.

Since 2001, federal deficits resulting from a number of fiscal pressures, including the wars in Afghanistan and Iraq, increased national defense spending and hurricane Katrina, have together placed significant stress on the resources available for U.S. biomedical research. Between the fiscal years 2004 and 2007, the National Cancer Institute’s budget remained relatively flat. However, factoring in inflation (i.e. a Biomedical Research and Development Price Index (BRDPI) of ~3.8% per year) reveals a 12% loss of purchasing power [1].

This decrease in resources comes as patient demand is growing. There was an estimated 1.5 million new cancer cases in 2007, an increase of 14% since 2001 [2]. The U.S. spends roughly $12 billion dollars every month fighting the wars in Afghanistan and Iraq. That’s 33 times more than what is spent on cancer research annually. Imagine what we could do if just a fraction of those resources was dedicated to cancer research.

Genomic Medicine: An Educational Resource from Helix Health

May 19, 2008 | by

The Human Genome Project has heralded a new era in our understanding of the molecular basis of disease. Genome-based medicine or personalized medicine is believed to be the future of healthcare. Indeed, genomic medicine is poised to improve disease diagnosis, therapy and prevention.

Although genomics is related to genetics, there is a difference between the two terms. Genetics is the study of single genes and their effects. In contrast, genomics is the study of all the genes in the genome and the interactions among them and their environment. Genetics uses the information from one or two genes to describe a disease state, whereas genomics examines all genetic information to determine biological markers predisposing a person to disease. Genomics is especially relevant for complex or multifactoral disorders such as cancer, Parkinson’s disease, heart disease and diabetes, which are due to the interaction of multiple genes and environmental factors [1].

Cancer Research Blog Carnival #7

March 7, 2008 | by

Welcome to the 7th edition of the Cancer Research Blog Carnival, a blog carnival devoted to cancer research. This edition includes some great articles on cancer research ethics, cancer therapeutics, cancer stem cells, cancer genetics and cancer biology.

There’s a revolution occurring on the Web: those “authoritative” articles written on traditional, static websites are being replaced with blogs, wikis and online social networks. In the sphere of health, medicine and information technology, this “real-time Web” consists of many who are professionals in the field; their posts are listed below.
In the digital age, these are the characteristics of new media: recent, relevant, reachable and reliable.

I believe it’s important to maintain perspective on the significance of cancer research and the impact it has on patients. As such, this months edition of the Cancer Research Carnival includes narratives from some people affected by the disease. I think their stories will inspire us all with their determination and courage, and serve as motivation to continue searching for therapies to combat cancer.cancer-research-logo.jpg